A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

U Platzbecker, A Symeonidis, E N Oliva, J S Goede, M Delforge, J Mayer, B Slama, S Badre, E Gasal, B Mehta, J Franklin, U Platzbecker, A Symeonidis, E N Oliva, J S Goede, M Delforge, J Mayer, B Slama, S Badre, E Gasal, B Mehta, J Franklin

Abstract

The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 weeks of subcutaneous darbepoetin alfa 500 μg or placebo every 3 weeks (Q3W), followed by 48 weeks of open-label darbepoetin alfa. A total of 147 patients were randomized, with median hemoglobin of 9.3 (Q1:8.8, Q3:9.7) g/dl and median baseline serum EPO of 69 (Q1:36, Q3:158) mU/ml. Transfusion incidence from weeks 5-24 was significantly lower with darbepoetin alfa versus placebo (36.1% (35/97) versus 59.2% (29/49), P=0.008) and erythroid response rates increased significantly with darbepoetin alfa (14.7% (11/75 evaluable) versus 0% (0/35 evaluable), P=0.016). In the 48-week open-label period, dose frequency increased from Q3W to Q2W in 81% (102/126) of patients; this was associated with a higher hematologic improvement-erythroid response rate (34.7% (34/98)). Safety results were consistent with a previous darbepoetin alfa phase 2 MDS trial. In conclusion, 24 weeks of darbepoetin alfa Q3W significantly reduced transfusions and increased rates of erythroid response with no new safety signals in lower-risk MDS (registered as EudraCT#2009-016522-14 and NCT#01362140).

Conflict of interest statement

UP: honoraria from Amgen Inc., Celgene, Janssen and Novartis. AS: research grants from Amgen Inc. ENO: honoraria from Celgene, Amgen Inc., La Jolla and speakers’ bureau for Novartis, Celgene. JSG: honoraria from Amgen Inc. MD: honoraria from Amgen Inc. JM: research grants from Amgen Inc. BS: none. SB, BM and JF: employees and stockholders of Amgen Inc. EG: Novartis employee, former Amgen Inc. employee.

Figures

Figure 1
Figure 1
Study design.
Figure 2
Figure 2
Patient disposition. aPrimary analysis sets. bSerum EPO⩽500 mU/ml locally but >500 mU/ml centrally, so patient was withdrawn. cFor adverse event (n=2), protocol (n=2), administrative (n=1) and other (n=1). dFor adverse event (n=2), consent withdrawn (n=1) and protocol (n=1). eColon adenocarcinoma (T1aN0M0) treated with polypectomy. fPer dosing algorithm (n=9), progression to AML (n=2, both prior darbepoetin alfa). gPer investigator (n=2), lack of response (n=2) and unknown (n=3).
Figure 3
Figure 3
Efficacy of darbepoetin alfa. (a) Transfusions assessed from week 5 onward to allow for the effects of darbepoetin alfa to be observed. (b) Erythroid response rates; reasons unevaluable for HI-E in the double-blind period (n=37) included transfusion in prior 28 days (n=33), no hemoglobin measurement within 14 days of first dose (n=3), did not receive darbepoetin alfa (n=1).

References

    1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
    1. Platzbecker U, Hofbauer LC, Ehninger G, Holig K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 2012; 36: 525–536.
    1. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943–2964.
    1. National Comprehensive Cancer Network I. Myelodysplastic Syndromes. 2016 (cited 3 March 2016); Available from .
    1. Onkologie DGfHuM. German S3 Leitlinie Guidelines. 2016 (cited 11 October 2016); Available from .
    1. Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008; 142: 379–393.
    1. Gotlib J, Lavori P, Quesada S, Stein RS, Shahnia S, Greenberg PL. A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 2009; 84: 15–20.
    1. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114: 2393–2400.
    1. Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K et al. A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. Int J Hematol 2015; 102: 401–412.
    1. Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Ades L et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013; 92: 621–631.
    1. Mannone L, Gardin C, Quarre MC, Bernard JF, Vassilieff D, Ades L et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006; 133: 513–519.
    1. Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008; 87: 527–536.
    1. Musto P, Lanza F, Balleari E, Grossi A, Falcone A, Sanpaolo G et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005; 128: 204–209.
    1. Nilsson-Ehle H, Birgegard G, Samuelsson J, Antunovic P, Astermark J, Garelius H et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ⩾120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions. Eur J Haematol 2011; 87: 244–252.
    1. Oliva EN, Nobile F, Alimena G, Specchia G, Danova M, Rovati B et al. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymph 2010; 51: 1007–1014.
    1. Park S, Fenaux P, Greenberg P, Mehta B, Callaghan F, Kim C et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol 2016; 174: 730–747.
    1. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111: 574–582.
    1. Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. J Support Oncol 2005; 3: 419–426.
    1. Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005; 16: 1921–1927.
    1. Villegas A, Arrizabalaga B, Fernandez-Lago C, Castro M, Mayans JR, Gonzalez-Porras JR et al. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 2011; 27: 951–960.
    1. Hellström-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Clin Haematol 2013; 26: 401–410.
    1. Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106: 803–811.
    1. Rigolin GM, Porta MD, Ciccone M, Bugli AM, Bragotti LZ, Mauro E et al. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol 2004; 126: 501–507.
    1. Smith SW, Sato M, Gore SD, Baer MR, Ke X, McNally D et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 2012; 97: 15–20.
    1. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.
    1. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 3607–3613.
    1. Symeonidis A, Zikos P, Galanopoulos A, Kotsianidis I, Kouraklis A, Protopapa M et al. Response to treatment with erythropoietin in patients with MDS highly predicts low risk of evolution to AML and longer survival. Leuk Res 2011; 35: S127–S128.
    1. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037–1046.
    1. Harnan S, Ren S, Gomersall T, Everson-Hock ES, Sutton A, Dhanasiri S et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Acta Haematol 2016; 136: 23–42.
    1. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425.
    1. Terpos E, Mougiou A, Kouraklis A, Chatzivassili A, Michalis E, Giannakoulas N et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002; 118: 174–180.
    1. Fenaux P, Adès L. How we treat lower-risk myelodysplastic syndromes. Blood 2013; 121: 4280–4286.
    1. Diez Campelo M, Lorenzo JI, Benlloch L, Lopez-Pavia M, Such E, Bernal T et al. Spanish registry of erythropoietic stimulating agents study: The largest retrospective study of ESAs for the treatment of anemia in lower risk MDS patients. Leuk Res 2015; 39: S105–S106.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi